Samvedna

Computational biologist with a PhD in Biological Sciences and Engineering, specialising in in silico antibody design, structural modelling, and molecular mechanism analysis in the context of cancer immunotherapy and viral targets. Proficient in AlphaFold2, AutoDock, GROMACS, I-TASSER, and PyMOL for protein structure prediction, binding interface analysis, and therapeutic optimisation at a molecular level. Author of six peer-reviewed publications including work in the Journal of Biomolecular Structure and Dynamics, with a focused body of work on bispecific antibody engineering, framework mutagenesis, and cross-reactive antibody characterisation. Developed an ML-based immunogenic peptide prediction pipeline using Python and scikit-learn (ROC-AUC 88.3%), with hands-on experience in building and documenting bioinformatics workflows. Actively contributed to the New AI-Empowered Platform for Sterically Guided Design of Bispecific Antibodies programme at BIOMEDX and Servier, Paris-Saclay, gaining direct exposure to industry-grade computational antibody discovery workflows, translational decision-making, and cross-functional collaboration within a multidisciplinary research team. Seeking to bring this combined foundation in structural biology, ML-driven bioinformatics, and antibody engineering to a Computational Antibody Design role at Servier Symphogen.

• Recipient of the DST–SERB Junior Research Fellowship (2018) for developing mammalian cell culture platforms for bispecific antibody production.
• ICDD 2020 by Schrödinger, BITS-Pilani Hyderabad, BiTE Sequence Optimization, 2020-01-01
• 14th Vaccine Congress, 2020-01-01, In-silico Optimization of Anti-CD3
• National Conference at Sharda University, 2021-01-01, Dual Specific Antibodies in Immunotherapy

• ORCHID [https://orcid.org/my-orcid?orcid=0000-0002-3374-2970]
• LinkedIN [https://www.linkedin.com/in/samvedna-s-23259a7b/]
• GitHub [https://www.linkedin.com/in/samvedna-s-23259a7b/]

1. Structural and functional analysis of engineered antibodies for cancer immunotherapy – J Biomol Struct Dyn, 2024.
2. Investigating the structural impact of Omicron RBD mutation – J Biomol Struct Dyn, 2024.
3. Exploring the role of framework mutations in a cross-reactive antibody (CR3022) – JBMSD, 2023.
4. A facile method for dual expression of recombinant protein – Protein Expr Purif, 2019.
5. Book Chapter: Bispecific Antibodies – A Promising Entrant in Cancer Immunotherapy, Elsevier, 2021.
6. A nanotherapeutic approach for fighting the odds against the malignant disorders-Journal of nanoparticle research, 2023.

• I love exploring new places to learn about their culture & cuisine and spending quiet moments reading with coffee in hand.